Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Receives Average Recommendation of “Moderate Buy” from Brokerages

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) has earned a consensus rating of “Moderate Buy” from the nine research firms that are covering the stock, Marketbeat Ratings reports. Six equities research analysts have rated the stock with a hold rating, one has assigned a buy rating and two have assigned a strong buy rating to the company. The average 1 year price objective among analysts that have covered the stock in the last year is $32.00.

Several research firms have recently weighed in on CPRX. Robert W. Baird downgraded Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 7th. Weiss Ratings raised shares of Catalyst Pharmaceuticals from a “buy (b-)” rating to a “buy (b)” rating in a report on Wednesday, June 3rd. Wall Street Zen downgraded shares of Catalyst Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, May 9th. Oppenheimer cut shares of Catalyst Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Thursday, May 7th. Finally, Stephens set a $32.00 price objective on shares of Catalyst Pharmaceuticals in a research report on Thursday, May 7th.

Institutional Investors Weigh In On Catalyst Pharmaceuticals

Several hedge funds have recently made changes to their positions in the business. Deerfield Management Company L.P. grew its stake in shares of Catalyst Pharmaceuticals by 72.8% in the 3rd quarter. Deerfield Management Company L.P. now owns 4,974,767 shares of the biopharmaceutical company’s stock valued at $98,003,000 after purchasing an additional 2,095,291 shares during the last quarter. Janus Henderson Group PLC increased its holdings in shares of Catalyst Pharmaceuticals by 200.6% in the fourth quarter. Janus Henderson Group PLC now owns 1,719,767 shares of the biopharmaceutical company’s stock valued at $40,124,000 after purchasing an additional 1,147,565 shares during the period. Morgan Stanley raised its stake in shares of Catalyst Pharmaceuticals by 59.1% during the fourth quarter. Morgan Stanley now owns 2,933,399 shares of the biopharmaceutical company’s stock worth $68,466,000 after purchasing an additional 1,089,775 shares during the last quarter. Bank of America Corp DE raised its stake in shares of Catalyst Pharmaceuticals by 38.0% during the first quarter. Bank of America Corp DE now owns 3,036,546 shares of the biopharmaceutical company’s stock worth $75,185,000 after purchasing an additional 836,704 shares during the last quarter. Finally, Glenmede Investment Management LP lifted its holdings in shares of Catalyst Pharmaceuticals by 781.8% during the third quarter. Glenmede Investment Management LP now owns 680,224 shares of the biopharmaceutical company’s stock worth $13,400,000 after purchasing an additional 603,084 shares during the period. Institutional investors and hedge funds own 79.22% of the company’s stock.

Catalyst Pharmaceuticals Price Performance

NASDAQ:CPRX opened at $31.49 on Thursday. The company has a market capitalization of $3.86 billion, a PE ratio of 18.10, a P/E/G ratio of 0.96 and a beta of 0.74. Catalyst Pharmaceuticals has a 52-week low of $19.05 and a 52-week high of $32.56. The stock’s 50 day moving average price is $31.42 and its 200 day moving average price is $27.82.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).